Home > Internet > An Invisible Gem stone Of PIK-3

An Invisible Gem stone Of PIK-3

Added: (Wed Sep 13 2017)

Pressbox (Press Release) - The complete response (CR) rate after chemotherapy in our series was 57% which is comparable to that seen in other studies [28], [29], [32]?and?[45] reporting CR rates that range between 52% and 67%. In our study, the median OS and PFS rates were 31 and 14?months respectively; and the two-year OS and PFS rates were 56% and 41% respectively. Survival rates in the current study were similar to those reported by many studies [29], [32], [33], [45]?and?[46]. Higher 2-year OS (67%) was reported in a study from Singapore [29]. Also, Cirillio et al. [37] reported a median OS of 54?months, with 46% of patients surviving at 5?years. Liang et al. [28] reported the experience in the management of 425 Chinese patients with primary GILs in Hong Kong over a period of 18?years. The OS of all patients was 45% at 5?years. Multivariate analysis revealed that age below 60?years, low grade histology, Lenvatinib datasheet stage I or II disease and absence of bulky tumor were PIK-3 independent prognostic factors predicting better OS. Similar to several studies [28], [46]?and?[47], MZ subtype had a better prognosis than other subtypes included in our study particularly DLBC. In our study, gastric involvement had a better OS and PFS than intestinal involvement. However, the difference did not reach statistical significance. In a 15-year review of 75 cases of GILs from North India and after a mean follow-up of 4?years, the 5-year OS rates were 34%, 25% and 16% for stages I, II, or>II, respectively. The survival rate was significantly better for gastric location Small Molecule Compound Library (44%) compared to other sites (24%) (p? Submitted by:

Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.